Edwards Lifesciences (NYSE:EW) Sets New 12-Month High – What’s Next?

Edwards Lifesciences Corporation (NYSE:EW) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $87.21 and last traded at $86.5270, with a volume of 1124743 shares traded. The stock had previously closed at $85.58.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Wells Fargo & Company increased their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a report on Thursday, August 7th. Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. Piper Sandler restated an “overweight” rating and issued a $95.00 price objective (up from $90.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. Finally, Canaccord Genuity Group reissued a “hold” rating and issued a $84.00 price target (up from $81.00) on shares of Edwards Lifesciences in a report on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Price Performance

The stock has a fifty day moving average of $77.99 and a two-hundred day moving average of $77.59. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $49.96 billion, a price-to-earnings ratio of 12.41, a PEG ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences’s quarterly revenue was up 14.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 1,020 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 22,970 shares of company stock worth $1,862,878 in the last quarter. 0.34% of the stock is owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in shares of Edwards Lifesciences by 0.5% during the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after buying an additional 365,581 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Edwards Lifesciences by 8.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after acquiring an additional 1,423,365 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after acquiring an additional 2,287,783 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Edwards Lifesciences by 0.4% in the second quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock valued at $990,074,000 after purchasing an additional 45,555 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in shares of Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after purchasing an additional 4,805,819 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.